Binimetinib-d4

• Description :

  Binimetinib-d4 (MEK162-d4) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.

• CAS Number :

  [2890696-60-1]

• Product Name Alternative :

  MEK162-d4; ARRY-162-d4; ARRY-438162-d4

• UNSPSC :

  12352005

• Target :

  Autophagy; Isotope-Labeled Compounds; MEK

• Related Pathways :

  Autophagy; MAPK/ERK Pathway; Others

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer

• Smiles :

  FC1=C(NC2=C(F)C(N=CN3C)=C3C=C2C(NOC([2H])([2H])C([2H])([2H])O)=O)C=CC(Br)=C1

• Molecular Formula :

  C17H11D4BrF2N4O3

• Molecular Weight :

  445.25

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Cheng H, et al. PIK3CA (H1047R) - and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35 (23) :2961-70.|[3]Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7 (15) :19997-20015.|[4]Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6 (39) :42183-96.|[5]J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.|[6]Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123 (6), 2551-2563.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported